Kadesjö E, Roos A, Siddiqui AJ, et al. - Researchers investigated whether reduced mortality and cardiovascular events in patients with type 2 myocardial infarction (T2MI), and non‐ischemic (acute or chronic) myocardial injury can be achieved with groups of treatment with angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, β‐blockers, statins, and platelet inhibitors. Also, it was determined if the decreased mortality would rely on the number of drugs used. Adjusted hazard ratios with 95% CI were estimated for all‐cause death in correlation with the number of medications (grouped as 0–1 [referent], 2–3 and 4 medications) in the groups of myocardial injury. Findings revealed infrequent prescribing of common cardiovascular medications to patients with T2MI and non‐ischemic acute or chronic myocardial injury vs patients with type 1 myocardial infarction. However, a lower risk of death was observed, following adjustment for confounders, in correlation with treatment with guideline recommended drugs in patients with T2MI and acute or chronic myocardial injury.